Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate that is under development for the treatment of pancreatic cancer[1] and other gastrointestinal cancers.
[2] It consists of a monoclonal antibody (indusatumab) that targets the enzyme guanylate cyclase 2C which is present in some cancers, linked to an average of three to four molecules of the chemotherapeutic agent monomethyl auristatin E (MMAE).
[3] It was in Phase II clinical trials as of February 2016[update].
This antineoplastic or immunomodulatory drug article is a stub.
You can help Wikipedia by expanding it.This monoclonal antibody–related article is a stub.